Old Web
English
Sign In
Acemap
>
authorDetail
>
Sameer R. Ghate
Sameer R. Ghate
Novartis
Medicine
Melanoma
Internal medicine
Oncology
Dabrafenib
4
Papers
18
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Cost-effectiveness of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US healthcare payer perspective
2019
Journal of Medical Economics
Margaret E. Gerbasi
Daniel R. Stellato
Sameer R. Ghate
Briana Ndife
Aaron Moynahan
Dinesh Mishra
P Gunda
Roy Koruth
Thomas E. Delea
Show All
Source
Cite
Save
Citations (7)
Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
2019
Journal of Clinical Oncology
Jason J. Luke
Sameer R. Ghate
Jonathan Kish
Choo Hyung Lee
Briana Ndife
Lindsay McAllister
Sonam Mehta
Antonio Nakasato
Bruce A. Feinberg
Show All
Source
Cite
Save
Citations (0)
Budget Impact of Dabrafenib and Trametinib in Combination as Adjuvant Treatment of BRAF V600E/K Mutation-Positive Melanoma from a U.S. Commercial Payer Perspective
2019
Journal of Managed Care Pharmacy
Daniel R. Stellato
Margaret E. Gerbasi
Briana Ndife
Sameer R. Ghate
Aaron Moynahan
Dinesh Mishra
P Gunda
Roy Koruth
Thomas E. Delea
Show All
Source
Cite
Save
Citations (5)
Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly
2018
American health & drug benefits
Sameer R. Ghate
Zhiyi Li
Jackson Tang
Antonio Nakasato
Show All
Source
Cite
Save
Citations (6)
1